Assignment 2: Assessing and Treating Patients With Sleep/Wake Disorders

Assignment 2: Assessing and Treating Patients With Sleep/Wake Disorders

Walden University Assignment 2: Assessing and Treating Patients With Sleep/Wake Disorders-Step-By-Step Guide

This guide will demonstrate how to complete the Walden University Assignment 2: Assessing and Treating Patients With Sleep/Wake Disorders assignment based on general principles of academic writing. Here, we will show you the A, B, Cs of completing an academic paper, irrespective of the instructions. After guiding you through what to do, the guide will leave one or two sample essays at the end to highlight the various sections discussed below.

How to Research and Prepare for Assignment 2: Assessing and Treating Patients With Sleep/Wake Disorders                           

Whether one passes or fails an academic assignment such as the Walden University Assignment 2: Assessing and Treating Patients With Sleep/Wake Disorders depends on the preparation done beforehand. The first thing to do once you receive an assignment is to quickly skim through the requirements. Once that is done, start going through the instructions one by one to clearly understand what the instructor wants. The most important thing here is to understand the required format—whether it is APA, MLA, Chicago, etc.

After understanding the requirements of the paper, the next phase is to gather relevant materials. The first place to start the research process is the weekly resources. Go through the resources provided in the instructions to determine which ones fit the assignment. After reviewing the provided resources, use the university library to search for additional resources. After gathering sufficient and necessary resources, you are now ready to start drafting your paper.

How to Write the Introduction for Assignment 2: Assessing and Treating Patients With Sleep/Wake Disorders                         

The introduction for the Walden University Assignment 2: Assessing and Treating Patients With Sleep/Wake Disorders is where you tell the instructor what your paper will encompass. In three to four statements, highlight the important points that will form the basis of your paper. Here, you can include statistics to show the importance of the topic you will be discussing. At the end of the introduction, write a clear purpose statement outlining what exactly will be contained in the paper. This statement will start with “The purpose of this paper…” and then proceed to outline the various sections of the instructions.

How to Write the Body for Assignment 2: Assessing and Treating Patients With Sleep/Wake Disorders                         

After the introduction, move into the main part of the Assignment 2: Assessing and Treating Patients With Sleep/Wake Disorders assignment, which is the body. Given that the paper you will be writing is not experimental, the way you organize the headings and subheadings of your paper is critically important. In some cases, you might have to use more subheadings to properly organize the assignment. The organization will depend on the rubric provided. Carefully examine the rubric, as it will contain all the detailed requirements of the assignment. Sometimes, the rubric will have information that the normal instructions lack.

Another important factor to consider at this point is how to do citations. In-text citations are fundamental as they support the arguments and points you make in the paper. At this point, the resources gathered at the beginning will come in handy. Integrating the ideas of the authors with your own will ensure that you produce a comprehensive paper. Also, follow the given citation format. In most cases, APA 7 is the preferred format for nursing assignments.

How to Write the Conclusion for Assignment 2: Assessing and Treating Patients With Sleep/Wake Disorders                         

After completing the main sections, write the conclusion of your paper. The conclusion is a summary of the main points you made in your paper. However, you need to rewrite the points and not simply copy and paste them. By restating the points from each subheading, you will provide a nuanced overview of the assignment to the reader.

How to Format the References List for Assignment 2: Assessing and Treating Patients With Sleep/Wake Disorders                           

The very last part of your paper involves listing the sources used in your paper. These sources should be listed in alphabetical order and double-spaced. Additionally, use a hanging indent for each source that appears in this list. Lastly, only the sources cited within the body of the paper should appear here.

Stuck? Let Us Help You

Completing assignments can sometimes be overwhelming, especially with the multitude of academic and personal responsibilities you may have. If you find yourself stuck or unsure at any point in the process, don’t hesitate to reach out for professional assistance. Our assignment writing services are designed to help you achieve your academic goals with ease. 

Our team of experienced writers is well-versed in academic writing and familiar with the specific requirements of the Assignment 2: Assessing and Treating Patients With Sleep/Wake Disorders assignment. We can provide you with personalized support, ensuring your assignment is well-researched, properly formatted, and thoroughly edited. Get a feel of the quality we guarantee – ORDER NOW. 

Sample Answer for NURS 6630 Assignment 2: Assessing and Treating Patients With Sleep/Wake Disorders

Introduction to the Case

The case scenario provided is of a 31year old male whose chief complaint is insomnia that has been worse in the past 6 months. Previously, he reports enjoying restful sleep although for the past 6months he has experienced both difficulties in falling and staying asleep. He even associates the onset of these sleep problems with the loss of his fiancé consequently leading to the loss. During the interview with the clinic, he explains that the problem is a bother because it has interfered with his job where because he experiences sleepiness during the day thus affecting his concentration and productivity at the workplace. He reports recent dependence on alcohol to help him fall asleep. The mental status examination performed on him revealed no abnormality in the orientation appearance, insight, and judgment.

A comprehensive assessment of this case study shows that the patient’s insomnia might be related to his psychological dysfunction resulting from the loss of his fiancé 6months ago. The sudden loss of a dear one triggers a myriad of psychiatric conditions even if the individual has no prior history of psychiatric conditions (Seiler et al., 2020). One of these psychiatric conditions is depression which is especially triggered by

complicated grief. The affected individual would therefore present with low mood, intense sadness, low energy, and loss of interest in activities of pleasure. They may also report sleep disturbances with insomnia being more common than hypersomnolence (Hasin et al., 2018). Managing the depression through medications or psychotherapy would help to relieve the patient’s symptoms such as insomnia that is suspected to arise from depression. The objective of this paper is to discuss how the patient in the case study was managed by describing the therapeutic options at Decision points 1, point 2, and point 3.

Decision Point One

For the initial management of the patient, I would prescribe 50mg of trazodone to be taken orally at bedtime daily. Trazodone is a drug that acts in the brain by reducing the reuptake of different neurochemicals in the brain such as serotonin but antagonizing the alpha-1-adrenergic and histamine receptors in the brain (Cuomo et al., 2019). By so doing, the serotonin levels in the brain are increased as well as the intensity of their action. Given depression results from an imbalance of brain neurochemicals such as serotonin and norepinephrine, increased serotonin levels resulting from trazodone use can lead to improved serotonergic actions thus treating depression and its symptoms (Hasin et al., 2018). When trazodone is therefore prescribed, the symptoms of depression including insomnia, appetite changes, and mood changes are corrected (Wang et al., 2020). It would therefore be the first-line medication for this patient.

Click here to ORDER an A++ paper from our MASTERS and DOCTORATE WRITERS: Assignment 2: Assessing and Treating Patients With Sleep/Wake Disorders

At decision point one, the foregone options are the 10mg zolpidem taken daily at bedtime or 50mg hydroxyzine taken daily at bedtime. Although zolpidem is effective in the management of insomnia by promoting the action of gamma-aminobutyric acid (GABA) in the brain, its side effect profile which includes drowsiness, complex sleep-related behavior and volition usually limit its use as a first-line medication for insomnia (Edinoff et al., 2021). Hydroxyzine has also been foregone because of its anticholinergic effects such as xerophthalmia and xerostomia (Hasin et al., 2018). Further, neither of these drugs is effective for the management of depression that has been linked with the patient’s insomnia.

The ethical principles require that the health care providers do not harm the patient. At point one, increasing the pill burden by prescribing the antidepressants separately from the drugs addressing insomnia would pose the risk of adverse drug reactions as well as increase the incidence of poor drug compliance (Bipeta, 2019). The ethical principle of non-maleficence would therefore require for prescription of a single agent that could manage both depressive illness and insomnia (Seiler et al., 2020). As such, trazodone is the preferred medication to the other provided options.

Decision Point Two

After 2 weeks of therapy with 50mg of trazodone at bedtime daily, the patient reports experiencing a prolonged erection in the morning that lasts 15 minutes but is undesired and affects his morning preparation for work although his sleeping has improved. At this point, the choice is to be made on how to address the prolonged erection. My decision at this step would be to explain to the patient that this prolonged erection is not priapism and would resolve over time. Thereafter, the current drug dose could be continued for patient care.

One of the undesired side effects of trazodone use is the prolonged erection caused. Through its α-adrenergic antagonism, the drug can lead to dilatation of vessels in the penis thus resulting in prolonged erection (Cuomo et al., 2019). The patient in the case study reports such prolonged undesired erection that lasts for approximately 15 minutes and thus cannot be considered priapism which usually lasts for up to 4hours (Hasin et al., 2018). However, the patient requires reassurance about the side effect profile of the drug, especially with the emphasis that the symptoms would dissipate with time (Cuomo et al., 2019). This would enhance adherence to therapy despite the drug’s side effects.

The other options at decision point 2 were either to discontinue trazodone and initiate 10mg suvorexant daily therapy or to decrease the dose of trazodone to 25mg daily at bedtime. The negative side effect of suvorexant includes daytime drowsiness thus its contraindication for this patient who operates a forklift. On the other hand, decreasing the dose of trazodone to 25mg daily may not be adequate to correct insomnia (Seiler et al., 2020). Patient education on the drug’s side effects, as well as reassurance, would therefore be opted for at this step.

At this decision point 2 where the patient reports the drug’s side effects, it would be ethical to truthfully educate him on the drug’s side effects to anticipate. Medications may be discontinued if necessary to prevent more harm to the patient (Bipeta, 2019). These honor ethical principles of beneficence and non-maleficence.

Decision Point Three

2 weeks after reassuring and educating the patient on the side effects of trazodone, he now reports that the priapism has resolved although he now experiences increased drowsiness during the next day. His insomnia has also resolved at 50mg of trazodone. At this step, I would continue the patient therapy at 50mg although the dose is split in half, and the patient is reassessed after a month.

As had been alluded to, trazodone is associated with increased drowsiness that may limit its use although the occurrence of such side effects is either rare or mild. However, when such drowsiness occurs, a reduction of the drug dose by 50% may be necessary as this may result in a reduction in drowsiness (Cuomo et al., 2019). The patient should however be adequately educated on how to split the drug dose so that the required drug dose is maintained. Further, patient follow-up within 4weeks would also be indicated to help in reassessing the effectiveness of the drug as well as the persistence of the drowsiness at 50% of the dose (Wang et al., 2020).

The other options provided at decision point 3 included either discontinuing trazodone and initiating sonata at 10mg nightly or replacing trazodone with 50mg of hydroxyzine at bedtime. Both of these options are not appropriate as they involved replacing trazodone that the patient has shown partial response to. Further, both sonata and hydroxyzine have worse side effect profile that limits their administration in this patient (Hasin et al., 2018).

At this decision point, the ethical principle of patient autonomy may affect further care. For instance, the patient may prefer either sonata or hydroxyzine to the in-use trazodone thus they can be prescribed despite their side effect profile (Bipeta, 2019). Such prescription seeks to promote the role of patients in their treatment.

Conclusion

Individuals presenting with any signs and symptoms at the clinic should be suspected and examined for any underlying conditions responsible for such presentation. For instance, a patient with insomnia may have underlying anxiety or depression. In managing these patients, the drugs prescribed should aim at correcting the underlying psychological disorder instead of addressing the signs and symptoms such as insomnia. specifically for this patient whose insomnia was thought to result from depression due to complicated grief, trazodone which is an antidepressant was prescribed at decision point one because of its effectiveness in managing insomnia (Cuomo et al., 2019). When he returns to the clinic with complaints of prolonged erection, the patient would be reassured with the emphasis that the symptoms would disappear with time. The patient would also be adequately educated on the adverse effects of the drugs to encourage drug compliance as they would be anticipating these side effects (Hasin et al., 2018). Thereafter, when he comes complaining of drowsiness, the drug dose would be reduced by 50% to resolve the symptoms. At either of the steps, the drugs’ side effects profile, as well as effectiveness, are compared before an effective drug with the least side effects is prescribed.

References

Bipeta, R. (2019). Legal and ethical aspects of mental health care. Indian Journal of Psychological Medicine, 41(2), 108–112. https://doi.org/10.4103/IJPSYM.IJPSYM_59_19

Cuomo, A., Ballerini, A., Bruni, A. C., Decina, P., Di Sciascio, G., Fiorentini, A., Scaglione, F., Vampini, C., & Fagiolini, A. (2019). Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice. Rivista Di Psichiatria, 54(4), 137–149. https://doi.org/10.1708/3202.31796

Edinoff, A. N., Wu, N., Ghaffar, Y. T., Prejean, R., Gremillion, R., Cogburn, M., Chami, A. A., Kaye, A. M., & Kaye, A. D. (2021). Zolpidem: Efficacy and side effects for insomnia. Health Psychology Research, 9(1), 24927. https://doi.org/10.52965/001c.24927

Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018). Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry (Chicago, Ill.), 75(4), 336. https://doi.org/10.1001/jamapsychiatry.2017.4602

Seiler, A., von Känel, R., & Slavich, G. M. (2020). The psychobiology of bereavement and health: A conceptual review from the perspective of Social Signal Transduction Theory of Depression. Frontiers in Psychiatry, 11, 565239. https://doi.org/10.3389/fpsyt.2020.565239

Wang, J., Liu, S., Zhao, C., Han, H., Chen, X., Tao, J., & Lu, Z. (2020). Effects of trazodone on sleep quality and cognitive function in arteriosclerotic cerebral small vessel disease comorbid with chronic insomnia. Frontiers in Psychiatry, 11, 620. https://doi.org/10.3389/fpsyt.2020.00620

Sample Answer 2 for NURS 6630 Assignment 2: Assessing and Treating Patients With Sleep/Wake Disorders

To promote a comprehensive understanding of the treatment of a patient with insomnia, this discussion examines the case of a 31-year-old male patient diagnosed with insomnia. The patient reports being used to getting inadequate sleep most of his life. However, ever since he lost his fiancé about 6 months ago, he has been finding it hard to fall and stay asleep. Previously, the patient was using diphenhydramine to manage his insomnia but stopped due to the side effects experienced upon waking up. His work requires very high concentration levels which are greatly impacted by his inability to get enough sleep at night. The patient even reports that he has been falling asleep at work recently. As reported by the patient’s previous physician, he has a history of opiate abuse, which was developed when he was prescribed hydrocodone/APAP (acetaminophen) for managing pain associated with his broken ankle from skiing. The patient however denies use of opioid analgesics for the past 4 years. He however reports drinking alcohol every night to help him sleep. Mental status examination reveals no possibilities of comorbidities.

Several medications have been proven to be effective in the management of insomnia among adults. However, the choice of which medication to prescribe depends on several patient factors. For the patient in this discussion, such factors include his age, gender, and insomnia diagnosis. His previous use of diphenhydramine but with undesirable side effects will also be considered. His social history of losing his fiancé, history of opiate abuse, and use of alcohol will also play a significant role in determining the most effective drug choice. The purpose of this paper is to illustrate the decisions made in prescribing medication for the treatment of young adult patients with insomnia, in addition to the ethical consideration at each decision point.

 Decision #1

Selected Decision and Rationale

Out of the provided alternatives, starting the patient on trazodone 50mg once daily at bedtime seems to be the most appropriate decision. Trazodone is an antidepressant with a complex mode of action primarily associated with the inhibition of the serotonin pathway (Martsenkovskyi & Napryeyenko, 2019). The drug is frequently prescribed off-label for the management of chronic insomnia high tolerance levels and effectiveness in initiating and maintaining sleep (Winkelman, 2015; Grandner & Perlis, 2019). The initial dose of the drug for adults with insomnia usually ranges from 25 to 50mg once daily, but the dose may range to up to 150mg once daily depending on the treatment outcome (Sateia et al., 2017). The drug is administered orally with a rapid absorption rate that promotes a short onset of action with peak plasma concentration being attained within 30 minutes to 1 hour. It is metabolized primarily via the CYP2D6 and CYP3A4 pathways with reduced risks of toxicity and adverse events.

Zolpidem can be used in the management of insomnia but is associated with increased risks of life-threatening sleep behaviors hence should only be recommended in case there is no other safer alternative (Sateia et al., 2017). On the other hand, it was not appropriate to prescribe hydroxyzine, given it belongs to a similar class of drugs to diphenhydramine (antihistamines) which already displayed undesirable side effects which made the patient discontinue using the drug (Martsenkovskyi & Napryeyenko, 2019; Yi et al., 2018).

Expected Outcome

            In about four weeks, the patient is expected to report to the hospital with significantly improved sleeping patterns (Sateia et al., 2017). He should be able to sleep adequately through the night, and exhibit improved concentration and energy levels the following morning (Grandner & Perlis, 2019).

Ethical Considerations

            When treating adult patients, the PMHNP needs to uphold the patient’s privacy and confidentiality. Consequently, the patient’s decision must be respected to uphold his autonomy.

Decision #2

Selected Decision and Rationale

            Looking at the reported treatment outcome after four weeks, it was necessary to reduce the trazodone dose to 25 mg orally at bedtime. The decision was mainly based on the reported side effect of prolonged erection the following morning (Madari et al., 2021). The patient displayed a positive outcome of the drug in managing his insomnia which is an indication of potential effectiveness (Sateia et al., 2017; Akinnusi & El Solh, 2019). Studies show that when used at low doses, the risks of potential side effects of trazodone such as priapism are normally reduced (Winkelman, 2015; Martsenkovskyi & Napryeyenko, 2019). Additionally, it has been reported that in case of self-limiting side effects like prolonged erection, reducing the dose will promote the side effect disappearing within a shorter time, hence promoting the patient’s tolerance to the medication (Yi et al., 2018).

Explaining to the patient that the reported side effect is not priapism and will resolve with time, without altering the dose was not necessary as this would promote worsening of the side effect (Grandner & Perlis, 2019; Yi et al., 2018). Consequently, stopping trazodone and starting suvorexant was also inappropriate given that the patient’s response within the two weeks displayed great adherence to the medication with only one self-limiting side effect, which does not qualify termination of the treatment therapy (Martsenkovskyi & Napryeyenko, 2019).

Expected Outcome

            The reported side effects of prolonged erection in the morning are expected to diminish within the next 4 weeks upon reducing the dose to 25mg once daily (Sateia et al., 2017). The patient’s sleeping pattern is also expected to improve even further within this time (Yi et al., 2018).

Ethical Considerations

            With the obligation of preventing harm to the patient and respecting their autonomy, the PMHNP needed to consider the patient’s discomfort with the reported side effects of the drug (Grandner & Perlis, 2019). As such, it was necessary to observe ethical principles such as justice and nonmaleficence in promoting clinical decision which promotes using a lower dose of the drug, which is still effective to elicit desired effects (Madari et al., 2021).

Decision #3

Selected Decision and Rationale

            Looking at the available options in line with the reported outcome from the initial intervention, the last decision was to continue using the same drug, at the same frequency and dose and encourage sleep hygiene. The patient has displayed great adherence and tolerance to trazodone, as the previously reported side effect diminished (Winkelman, 2015). However, the dose was quite low, hence sometimes failing to help the patient sleep through the night. Studies show that at low doses, trazodone can take up to 8 to 12 weeks to completely help patients sleep through the night (Grandner & Perlis, 2019). Consequently, to avoid side effects associated with the use of several pharmacological agents, evidence supports the use of nonpharmacological interventions such as appropriate sleep hygiene to promote treatment outcomes (Sateia et al., 2017; Yi et al., 2018).

Replacing trazodone with ramelteon, which is a hypnotic was not necessary as the already displayed great tolerance and adherence to trazodone, and the latter is also associated with undesired cardiovascular side effects which might compromise the patient’s health (Martsenkovskyi & Napryeyenko, 2019). As stated earlier, replacing trazodone with hydroxyzine was also inappropriate as hydroxyzine being an antihistamine would only lead to undesired side effects which might affect the patient’s compliance with the medication (Grandner & Perlis, 2019).

Expected Outcome

At this point, the patient is expected to attain an adequate amount of sleep every night with the adoption of appropriate sleep hygiene (Winkelman, 2015). No side effects are expected. Patient productivity at work is expected to improve due to improved quality of sleep (Yi et al., 2018).

Ethical Considerations

Adult patients have the legal right of making sound decisions concerning their health. As such, the PMHNP must ensure that the patient is adequately acknowledged of the available treatment options, and the benefits and limitations of each choice (Grandner & Perlis, 2019). Respecting patient autonomy is also crucial in promoting trust and a positive care outcome (Martsenkovskyi & Napryeyenko, 2019).

Conclusion

Several drugs have been recommended for the management of insomnia among adults. However, the decision on which medication to prescribe greatly depends on several patient-specific factors. The provided case demonstrates a young adult male patient with worsening insomnia. The patient was initially taking phenylhydrazine for the management of his insomnia but did not like the way it made him feel the following morning. Out of the available options, the first decision was to start the patient on trazodone 50mg orally every night. The drug has been approved by the FDA for the management of depression, but due to its tolerance and great effectiveness in the management of chronic insomnia, it is frequently prescribed doff label (Winkelman, 2015). Zolpidem and hydroxyzine were thus neglected due to their increased risks of toxicity (Martsenkovskyi & Napryeyenko, 2019). After two weeks, the patient came back to the hospital complaining of prolonged erection the following morning, but with well-managed insomnia (Akinnusi & El Solh, 2019). This outcome led to the second decision which was to reduce the dose of the drug to 25 mg every night (Yi et al., 2018). Discontinuing the drug and initiating suvorexant instead was not appropriate due to associated safety risks (Madari et al., 2021).

The patient reported that the side effect diminished after 2 weeks, but the dose was quite low to keep him asleep through the night. As such, the final decision was to continue using the same drug at the same dose and consider sleep hygiene to promote the treatment outcome (Sateia et al., 2017). In each decision process, the PMHNP was forced to observe several ethical principles including justice, autonomy, nonmaleficence, and observing the patient’s privacy and confidentiality (Grandner & Perlis, 2019). The patient was also adequately informed about each decision process, in terms of all the available options with their benefits and limitations.

 References

Akinnusi, M., & El Solh, A. A. (2019). Drug treatment strategies for insomnia in patients with post-traumatic stress disorder. Expert Opinion on Pharmacotherapy, 20(6), 691–699. https://doi.org/10.1080/14656566.2019.1574745

Grandner, M. A., & Perlis, M. L. (2019). Pharmacotherapy for Insomnia Disorder in Older Adults. JAMA Network Open, 2(12), e1918214. https://doi.org/10.1001/jamanetworkopen.2019.18214

Madari, S., Golebiowski, R., Mansukhani, M. P., & Kolla, B. P. (2021). Pharmacological Management of Insomnia. Neurotherapeutics. https://doi.org/10.1007/s13311-021-01010-z

Martsenkovskyi, D., & Napryeyenko, O. (2019). P.818 Adjunctive therapy with trazodone for insomnia in adolescents with post-traumatic stress disorder and depression. European Neuropsychopharmacology, 29, S543–S544. https://doi.org/10.1016/j.euroneuro.2019.09.682

Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017). Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine, 13(02), 307–349. https://doi.org/10.5664/jcsm.6470

Winkelman, J. W. (2015). Insomnia Disorder. New England Journal of Medicine, 373(15), 1437–1444. https://doi.org/10.1056/nejmcp1412740

Yi, X., Ni, S., Ghadami, M. R., Meng, H., Chen, M., Kuang, L., Zhang, Y., Zhang, L., & Zhou, X. (2018). Trazodone for the treatment of insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Medicine, 45, 25–32. https://doi.org/10.1016/j.sleep.2018.01.010

Sample Answer 3 for NURS 6630 Assignment 2: Assessing and Treating Patients With Sleep/Wake Disorders

Insomnia is one of the sleep disorders that affect most of the patients visiting the psychiatric clinic. A patient is diagnosed with insomnia if the symptoms occur for a period of at least three weeks and persists for three or more months despite the adequacy of sleep opportunities. Patients with insomnia often complain of sleep dissatisfaction. Therefore, this case analysis focuses on a 31-year old patient who visited the clinic with complains of insomnia. The client reported that his insomnia has worsened over the past six months. He also reported that he has never been a great sleeper. However, the patient reported that he is now having difficulties in falling asleep and staying asleep at night. The symptoms of insomnia started about six months ago after she lost his fiancé. The client reported that the insomnia has affected his ability to perform his job. Patient factors will influence the decisions that are made in this case study. The factors include his past use of diphenhydramine to induce sleep but do not like how he feels after. The other is his past medical record that shows that he has a history of opiate abuse, which started when he broke his ankle while skiing. The patient’s use of alcohol to help him fall asleep will also be considered, as he reported to drink approximately four beers before going to bed.

Decision Point 1

Selected Decision

The selected decision for the patient at this stage is the administration of Zolpidem 10 mg daily at bedtime.

Reason for the Selection

Zolpidem is a non-benzodiazapine GABA-A receptor agonist receptor that is recommended for use in treatment of insomnia. According to Castro et al., (2020), non-benzodiazepine GABA-A agonists are considered the standard treatment drugs for insomnia treatment. Zolpidem is a drug that belongs to this drug that produces its therapeutic effect by reducing the sleep latency as well as the frequency of nocturnal awakenings. The drug also increases the total sleep time and sleep efficiency in patients with insomnia (Castro et al., 2020). The Food and Drug Administration recommends that Zolpidem should be initiated in lower doses to reduce the adverse events as well as residual impairment. The recommendation informs the decision to initiate the patient with a dose of 10 mg bedtime to minimize the risk of side effects of the drug (Yu et al., 2017). The use of Zolpidem also produces hypnotic effect and highly tolerated for patients with insomnia (Nishimura & Nakao, 2018). Zolipdem has also been shown to have a high rate of absorption as well as distribution once administered. The above effects promote enhanced sleep maintenance and sleep latency. The drug also has weak myorelxant, anticonvulsant and anxiolytic effects that make it desirable for use in insomnia (Machado et al., 2020). Based on the above, Zolpidem was considered the first line drug for treating the patient in this case study.

Why the Other Options were not Selected

Trazodone 50-100 mg bedtime could have been considered for treating the patient in this case study. However, it has been shown to produce optimum effectiveness in patients with depression than those with insomnia. The use of Trazodone was also not selected because it has been shown in studies not to produce any improvement in sleep efficiency, latency, and quality in patients with insomnia (Yi et al., 2018). Hydroxyzine 50 mg daily at bedtime was not selected as the first line of treatment for the patient in this case study because the drug is used to augment the therapeutic effectiveness of medications that are used in the treatment of insomnia (Albrecht et al., 2019).

Expected Outcomes

The above decision was made with the aim of improving the sleep quality of the patient. The decision also aimed at improving the ability of the patient to fall asleep and stay asleep at night due to the hypnotic effect of the medication (Castro et al., 2020). The improvement in the sleep quality was also expected to result in enhanced social and occupational functioning of the patient. It was also anticipated that the administration of Zolpidem would lead to decline in incidences of daytime sleeping by the patient.

Ethical Consideration

The ethical principle that informed the selection of Zolpidem over other options of treatment was the promotion of safety in treatment. Zolpidem was found to have enhanced benefits over the other treatment options. The risk of adverse events was also minimal with optimal benefits for the patients (Mastroianni et al., 2019). Therefore, the selection was anticipated to promote safety in care.

Decision Point 2

Selected Decision

The selected decision at this point is to decrease the dose of Zolipdem to 5 mg daily at bedtime.

Reason for the Selection

The above decision was made because of the fact that the patient experienced the side effects of Zolpidem. Zolpidem is associated with side effects such as the patient feeling tired, weak, drowsy, loss of coordination, and confusion. The patient also experienced side effects such as forgetfulness and awakening at night. As a result, Castro et al., (2020) recommended that the dosage of Zolipdem should be reduced should the patient experience adverse events or residual impairment. Consequently, this recommendation was taken into consideration in reducing the dosage of Zolpidem to 5 mg daily at bedtime.

Why the Other Options were not Selected

The decision to discontinue zolpidem and initiate therapy with eszopiclone 1 mg daily at bedtime was not selected because it is associated with side effects that may lower the adherence by the patient. Eszopiclone is associated with severe side effects such as accidental injury, dizziness, urinary tract infection, upper respiratory tract infection, pain, dyspepsia, bitter taste, and diarrhea, which might lead to poor drug adherence by the patient. The recommended dose for the drug is also 3 mg administered for 12 months, implying that the current dose may not produce the desired therapeutic effect (Rösner et al., 2018). The decision to discontinue zoplidem and initiate trazodone 50-100 mg daily at bedtime was also not selected because it does not improve sleep efficiency, latency, and quality in patients with insomnia (Yi et al., 2018).

Expected Outcomes

The above decision was made with the aim of reducing the side effects of zolpidem. The aim was to reduce night awakening and eliminate the need for alcohol intake in using the medication in improving sleep quality. The decision also aimed at improving the ability of the patient to fall asleep and remain asleep for better quality of sleep. According to Machado et al., (2020), low dose of zolpidem is associated with less side effects and improved overall quality of sleep for patients with insomnia.

Ethical Consideration

The ethical principle that informed the above decision is benevolence and non-maleficence. The PMHNP made the decision with the aim of reducing the side effects of zolpidem while optimizing its therapeutic effectiveness. The PMHNP also aimed at ensuring that the best alternative from the choices was selected to improve adherence of the patient to the treatment (Mastroianni et al., 2019). Through it, it was anticipated that the desired treatment outcomes would be achieved.

Decision Point 3

Selected Decision

The selected decision is maintaining the dose of zolpidem and having the patient return in 4 weeks for follow up appointment.

Reason for the Selection

The above decision was made because the desired therapeutic effect of zolpidem had been achieved. The client returned to the clinic after 2 weeks reporting a great decline in nighttime activity. The girlfriend also reported that the client got up in one time and wanted to go for a drive in the two weeks. The patient also denied auditory or visual hallucinations and was future oriented. The patient also reported having positive experience with zolpidem and its ability to manage his symptoms of insomnia. As seen from the research by Castro et al., (2020), the effectiveness of zolpidem are evidenced by the improvement in sleep quality, duration, total sleep time, and latency, which have been achieved in this case study. Therefore, maintaining the current dosage is the best alternative to embrace at this time.

Why the Other Options were not Selected

The decision to discontinue zolpidem, initiate therapy with intermezzo sublingual tablet at bedtime as needed, and follow up in 4 weeks was not selected because the desired therapeutic effect of zolpidem had been achieved. Similarly, the decision to discontinue zolpidem and initiate trazodone was not selected because zolpidem had yielded the needed outcomes. Discontinuing is likely to increase the side effects being experienced by the patient.

Expected Outcomes

The above decision was made with the aim of sustaining the therapeutic effectiveness of zolpidem in managing symptoms of insomnia. It was anticipated that maintaining the dose will lead to a further decline in symptoms such as awakening of the patient at night. Maintaining the dose was also expected to result in enhanced tolerability by the patient (Machado et al., 2020).

Ethical Consideration

The ethical consideration that informed the decision made in this step is promotion of patient autonomy. The patient should be educated on the importance of medication adherence. He should also be educated on the risks of self-prescription of use of over the counter medications (Mastroianni et al., 2019). Therefore, it is anticipated that enhanced treatment adherence will be achieved in the management of the patient’s health problem.

Conclusion

Overall, the PMHNP demonstrated significant competence in treating the patient in this case study. The use of zolpidem was demonstrated to be effective in managing the symptoms of insomnia. The use of Zolpidem however requires close monitoring of the patients to determine any residual or side effects that need to be addressed on time. The case study has shown the importance of ethical considerations in treating patients with mental health problems. Therefore, the PMHNP should be aware of the ethical and professional issues that affect the decisions that they make in practice.

References

Albrecht, J. S., Wickwire, E. M., Vadlamani, A., Scharf, S. M., & Tom, S. E. (2019). Trends in Insomnia Diagnosis and Treatment Among Medicare Beneficiaries, 2006–2013. The American Journal of Geriatric Psychiatry, 27(3), 301–309. https://doi.org/10.1016/j.jagp.2018.10.017

Castro, L. S., Otuyama, L. J., Fumo-dos-Santos, C., Tufik, S., Poyares, D., Castro, L. S., Otuyama, L. J., Fumo-dos-Santos, C., Tufik, S., & Poyares, D. (2020). Sublingual and oral zolpidem for insomnia disorder: A 3-month randomized trial. Brazilian Journal of Psychiatry, 42(2), 175–184. https://doi.org/10.1590/1516-4446-2019-0389

Machado, F. V., Louzada, L. L., Cross, N. E., Camargos, E. F., Dang-Vu, T. T., & Nóbrega, O. T. (2020). More than a quarter century of the most prescribed sleeping pill: Systematic review of zolpidem use by older adults. Experimental Gerontology, 136, 110962. https://doi.org/10.1016/j.exger.2020.110962

Mastroianni, A. C., Kahn, J. P., & Kass, N. E. (2019). The Oxford Handbook of Public Health Ethics. Oxford University Press.

Nishimura, S., & Nakao, M. (2018). Cost-effectiveness analysis of suvorexant for the treatment of Japanese elderly patients with chronic insomnia in a virtual cohort. Journal of Medical Economics, 21(7), 698–703. https://doi.org/10.1080/13696998.2018.1466710

Rösner, S., Englbrecht, C., Wehrle, R., Hajak, G., & Soyka, M. (2018). Eszopiclone for insomnia. Cochrane Database of Systematic Reviews, 10. https://doi.org/10.1002/14651858.CD010703.pub2

Yi, X., Ni, S., Ghadami, M. R., Meng, H., Chen, M., Kuang, L., Zhang, Y., Zhang, L., & Zhou, X. (2018). Trazodone for the treatment of insomnia: A meta-analysis of randomized placebo-controlled trials. Sleep Medicine, 45, 25–32. https://doi.org/10.1016/j.sleep.2018.01.010

Yu, Z., Xu, X., Wang, S., Song, M., Liu, Y., Yin, Y., Mao, H., & Tang, G. (2017). Effect and safety of paroxetine combined with zolpidem in treatment of primary insomnia. Sleep and Breathing, 21(1), 191–195. https://doi.org/10.1007/s11325-017-1462-0